These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 19837296)

  • 21. Foot-and-mouth disease vaccine potency testing: the influence of serotype, type of adjuvant, valency, fractionation method, and virus culture on the dose-response curve in cattle.
    Jamal SM; Bouma A; van den Broek J; Stegeman A; Chénard G; Dekker A
    Vaccine; 2008 Nov; 26(50):6317-21. PubMed ID: 18822336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccines and foot-and-mouth disease eradication in South America.
    Saraiva V
    Dev Biol (Basel); 2003; 114():67-77. PubMed ID: 14677678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost.
    Li Y; Stirling CM; Denyer MS; Hamblin P; Hutchings G; Takamatsu HH; Barnett PV
    Vaccine; 2008 May; 26(21):2647-56. PubMed ID: 18321615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus.
    Brehm KE; Kumar N; Thulke HH; Haas B
    Vaccine; 2008 Mar; 26(13):1681-7. PubMed ID: 18313814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant effect of Cliptox on the protective immune response induced by an inactivated vaccine against foot and mouth disease virus in mice.
    Batista A; Quattrocchi V; Olivera V; Langellotti C; Pappalardo JS; Di Giacomo S; Mongini C; Portuondo D; Zamorano P
    Vaccine; 2010 Aug; 28(38):6361-6. PubMed ID: 20637310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pressure-inactivated FMDV: a potential vaccine.
    Ishimaru D; Sá-Carvalho D; Silva JL
    Vaccine; 2004 Jun; 22(17-18):2334-9. PubMed ID: 15149793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global FMD control--is it an option?
    Kitching P; Hammond J; Jeggo M; Charleston B; Paton D; Rodriguez L; Heckert R
    Vaccine; 2007 Jul; 25(30):5660-4. PubMed ID: 17126959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thermostable foot-and-mouth disease virus as a vaccine candidate for endemic countries: a perspective.
    Hegde NR; Maddur MS; Rao PP; Kaveri SV; Bayry J
    Vaccine; 2009 Apr; 27(16):2199-201. PubMed ID: 19189856
    [No Abstract]   [Full Text] [Related]  

  • 29. The current state of vaccines used in the field for foot and mouth disease virus in China.
    Li Z; Liu J
    Expert Rev Vaccines; 2011 Jan; 10(1):13-5. PubMed ID: 21162615
    [No Abstract]   [Full Text] [Related]  

  • 30. Very fast (and safe) inactivation of foot-and-mouth disease virus and enteroviruses by a combination of binary ethyleneimine and formaldehyde.
    Barteling SJ; Cassim NI
    Dev Biol (Basel); 2004; 119():449-55. PubMed ID: 15742659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of new adjuvants in an emergency vaccine against foot-and-mouth disease virus: evaluation of conferred immunity.
    Quattrocchi V; Bianco V; Fondevila N; Pappalardo S; Sadir A; Zamorano P
    Dev Biol (Basel); 2004; 119():481-97. PubMed ID: 15742663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expressions of Bovine IFN-gamma and foot-and-mouth disease VP1 antigen in P. pastoris and their effects on mouse immune response to FMD antigens.
    Shi XJ; Wang B; Zhang C; Wang M
    Vaccine; 2006 Jan; 24(1):82-9. PubMed ID: 16135391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An alternate delivery system improves vaccine performance against foot-and-mouth disease virus (FMDV).
    Pandya M; Pacheco JM; Bishop E; Kenney M; Milward F; Doel T; Golde WT
    Vaccine; 2012 Apr; 30(20):3106-11. PubMed ID: 22387223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospects, including time-frames, for improved foot and mouth disease vaccines.
    Grubman MJ; Mason PW
    Rev Sci Tech; 2002 Dec; 21(3):589-600. PubMed ID: 12523699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines.
    Robinson L; Knight-Jones TJ; Charleston B; Rodriguez LL; Gay CG; Sumption KJ; Vosloo W
    Transbound Emerg Dis; 2016 Jun; 63 Suppl 1():30-41. PubMed ID: 27320164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The application of biotechnology to the control of foot-and-mouth disease virus.
    Kitching RP
    Br Vet J; 1992; 148(5):375-88. PubMed ID: 1330200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine.
    Du Y; Li Y; He H; Qi J; Jiang W; Wang X; Tang B; Cao J; Wang X; Jiang P
    J Virol Methods; 2008 Apr; 149(1):144-52. PubMed ID: 18294705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvants for foot-and-mouth disease virus vaccines: recent progress.
    Cao Y
    Expert Rev Vaccines; 2014 Nov; 13(11):1377-85. PubMed ID: 25234962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of vaccines in South American foot-and-mouth disease eradication programmes.
    Saraiva V; Darsie G
    Dev Biol (Basel); 2004; 119():33-40. PubMed ID: 15742616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of an effective vaccine against foot-and-mouth disease with partially purified and concentrated virus antigen.
    Sen AK; Saha SN
    Acta Virol; 1994 Feb; 38(1):17-9. PubMed ID: 8067308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.